IRIDEX Corporation (NASDAQ:IRIX) Q1 2026 Earnings Call Transcript
IRIDEX Corporation reported its Q1 2026 earnings, with revenues of $11.8 million, essentially flat year-over-year, and beating EPS expectations with a reported $-0.03 against an expected $-0.07. The company's glaucoma business, particularly G-Probes, showed strong growth, but international retina sales were impacted by regulatory and supply chain issues. Despite these challenges, IRIDEX reaffirmed its full-year 2026 revenue guidance of $51 million to $53 million and expects to achieve positive cash flow from operations for the full year.
How this was made

The 30-second read
Why it matters
Earnings beat and reaffirmed guidance support a cautiously optimistic outlook, though international challenges introduce some uncertainty.
Market read
The company's recent earnings and product performance suggest potential short-term gains, but international sales issues warrant caution.
What to watch
Possible delays in international market recovery; competitive pressures in ophthalmology devices.
Background
IRIDEX reported stable revenues with notable growth in glaucoma products but faced international sales headwinds.
Ticker impact
Primary focus due to recent earnings report and positive sentiment.
Moderate upward movement in the short to medium term, driven by earnings beat and reaffirmed guidance.
Earnings beat expectations and reaffirmed guidance suggest positive momentum. However, international sales issues and overall flat revenue indicate caution. Technical indicators and industry comparisons support a moderate bullish outlook.
Market effects
Positive outlook for ophthalmology and life sciences sectors, especially companies with glaucoma and retina product lines.
Limited; primarily affects US-based ophthalmology companies.
Moderate; international sales challenges may influence global ophthalmology market dynamics.
Counterpoint
Potential overestimation of growth due to earnings beat; international sales issues could weigh on stock performance.
Key entities
- CompanyIRIDEX Corporation
A medical device company specializing in ophthalmology and dermatology products.
- ProductG-Probes
A glaucoma treatment device showing strong growth.





